Preclinical drug development chain. Red arrows indicate the status of current projects in the lab.
© dkfz.de

The DKFZ – Bayer HealthCare Joint Laboratory focuses on the development of cancer therapeutics that enhance the reactivity of the patient’s immune system against the tumor. New targets for immunotherapeutics are identified by scientists at DKFZ and Bayer. After target validation, which generally takes place in the lab of the lead PI at DKFZ or Bayer, the projects are transferred to the Joint Lab for further pre-clinical development. The aim is to jointly develop new drugs towards clinical testing in phase I trials. Our current pipeline encompasses nine intra- and extracellular targets from which we are developing small molecules and antibody therapeutics, respectively.

to top
powered by webEdition CMS